Acute myeloid leukemia (AML) Clinical Trials in Houston, TX

As of June 2026, 71 paid clinical trials are recruiting for Acute myeloid leukemia (AML) in Houston, Texas. Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Related specialties in Houston

Oncology· 1,692 Blood cancer· 367

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

71 clinical trials for Acute myeloid leukemia (AML)

·Clear filters·↓ Download CSV

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

164 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting

Apply to this trial

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

for Acute Myeloid Leukemia

1 location in Houston

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04953897·Phase 1·Recruiting

Apply to this trial

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT05010772·Phase 1·Recruiting

Apply to this trial

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18 - 70·Accepts healthy volunteers

Code: NCT04708054·Phase 2, Phase 3·Recruiting

Apply to this trial

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT05010122·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of BGB-11417 in Participants With Myeloid Malignancies

for Acute Myeloid Leukemia

5 locations incl. Duarte

Sponsor: BeiGene

Sex: All·Age: 18+

Code: NCT04771130·Phase 1, Phase 2·Recruiting

Apply to this trial

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04774393·Phase 1, Phase 2·Recruiting

Apply to this trial

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia With Gene Mutations

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04493164·Phase 2·Recruiting

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

49 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

185 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting

Apply to this trial

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

for Acute Myeloid Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT02390635·Phase 1·Recruiting

Apply to this trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

for Myelodysplastic Syndromes

Drug: Venetoclax

24 locations incl. Los Angeles

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04256317·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia

3 locations incl. Duarte

Sponsor: Edgewood Oncology Inc.

Sex: All·Age: 18+

Code: NCT04243785·Phase 1·Recruiting

Apply to this trial

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

for Recurrent Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04140487·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia

Drug: Revumenib

22 locations incl. Duarte

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 30 Days+

Code: NCT04065399·Phase 1, Phase 2·Recruiting

Apply to this trial

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04047641·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

for Acute Myeloid Leukemia

21 locations incl. Fountain Valley

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04093570·Phase 2·Enrolling By Invitation

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

for Acute Myeloid Leukemia

11 locations incl. Duarte

Sponsor: Orca Biosystems, Inc.

Sex: All·Age: 12 - 78

Code: NCT03802695·Phase 1·Recruiting

Apply to this trial

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT03661307·Phase 1, Phase 2·Recruiting

Apply to this trial

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

for Recurrent Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT03629171·Phase 2·Recruiting

Apply to this trial

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

for Acute Myeloid Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 50+

Code: NCT03586609·Phase 2·Recruiting

Apply to this trial

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

for Acute Myeloid Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 1+

Code: NCT03630991·Phase 1·Recruiting

Apply to this trial

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

for Acute Myeloid Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 12+

Code: NCT03589729·Phase 2·Recruiting

Apply to this trial

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

for Acute Bilineal Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT03683433·Phase 2·Recruiting

Apply to this trial

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

for Acute Myeloid Leukemia

Drug: Venetoclax

4 locations incl. Boston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT03471260·Phase 1, Phase 2·Recruiting

Apply to this trial

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

for Acute Myeloid Leukemia

3 locations incl. Baltimore

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 12+

Code: NCT03383575·Phase 2·Recruiting

Apply to this trial

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

for High Risk Myelodysplastic Syndrome

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT03214562·Phase 1, Phase 2·Recruiting

Apply to this trial

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

for Acute Myeloid Leukemia

Drug: Venetoclax

3 locations incl. Duarte

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT03113643·Phase 1·Recruiting

Apply to this trial

Personalized NK Cell Therapy in CBT

for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 15 - 80

Code: NCT02727803·Phase 2·Recruiting

Apply to this trial

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

for Recurrent Acute Lymphoblastic Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT02392572·Phase 1, Phase 2·Recruiting

Apply to this trial

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

for Acute Biphenotypic Leukemia

Drug: Venetoclax

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18 - 65

Code: NCT02115295·Phase 2·Recruiting

Apply to this trial